ReviewMolecules (Basel, Switzerland)2026
Multifunctional Nanomaterials for Precision Diagnostics and Drug Delivery: AI-Assisted Biosensing, Barrier-Directed Transport, Stimuli-Responsive Release, and Theranostic Integration.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Nanomaterials are increasingly expected to do more than transport a payload, yet added complexity is useful only when it resolves a rate-limiting diagnostic, transport, release, or monitoring problem. This review develops a function-first framework for precision diagnostics and drug delivery in which formation and processing are linked to nanoscale structure, material properties, demonstrated function, route-specific evidence, and translational value. The scope includes AI-assisted plasmonic and terahertz biosensing; biopolymer nanoparticles and hydrogel depots; barrier-directed nose-to-brain and systemic delivery; graphene and carbon nanotube interfaces; lipid nanoparticles for nucleic acid packaging and endosomal escape; nanoporous, magnetic, and plasmonic carriers; and closed-loop theranostic systems. A platform is treated as genuinely multifunctional only when at least two deliberately engineered functions are experimentally supported and either act on distinct rate-limiting steps or close a sensing-intervention-monitoring loop. This review therefore distinguishes total loading from bioavailable payload, cellular uptake from productive delivery, imaging labels from intact carrier fate, and nominal stimulus responsiveness from controlled release in response to a physiologically realistic trigger. Recent independent studies are used to broaden comparisons across material classes and to separate proof-of-concept performance from translational evidence. Artificial intelligence is considered in three distinct roles-sensor interpretation, formulation/material optimization, and prediction of in vivo behavior-with external validation and, where a model is intended to guide decisions, prospective testing treated as essential. The resulting framework emphasizes biological identity, route-specific safety, carrier-versus-payload tracking, critical quality attributes, manufacturing reproducibility, and a minimum-evidence roadmap from concept to product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.